Regina received a PhD in Cardiovascular Physiology/Pharmacology at the University of Göteborg in 1993. She then continued in academia for eight years.
During this time she worked at the University of Göteborg, University of Ottawa, University of Queensland and University of Nevada. In 1997 she became Associate Professor at the University of Göteborg.
Regina has a broad scientific background in human and animal physiology, particularly in cardiovascular physiology. She has published over 40 papers and several review articles and book chapters within the field. She has detailed knowledge in the area of atherosclerosis and cardiovascular physiology – including human disease pathophysiological mechanisms, medical need, current treatment and related pre-clinical science and capabilities.
During her sixteen years at AstraZeneca, Regina has worked in drug projects and been in project leader roles for drug projects from target discovery up to Phase 2 in clinical development, in addition to her line management responsibilities.
In January 2011, Regina was appointed Senior Director and strategy area lead for atherosclerotic cardiovascular disease and she was instrumental in establishing the Cardiac Regeneration research area focusing on heart failure. Regina also led the IMED Biotech Unit’s first mRNA programme, VEGF-A from start to Phase 2 clinical development. In 2014, Regina was appointed Head of Bioscience Department Heart Failure Department with overall accountability to initiate and progress the portfolio in the cardiovascular and heart failure area.
In 2017, she was promoted to Vice President and Head of Early Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D.